VIRTTU: <b>Virttu Biologics</b> Shows Robust Evidence Of Immunological Activity In Mesothelioma Patients Following SEPREHVIR Administration Results To Be Presented At <b>Society For ImmunoTherapy Of Cancer (SITC)</b>

GLASGOW, United Kingdom, Nov. 5, 2015 /PRNewswire/ --Virttu Biologics, a clinical stage oncolytic immunotherapeutic company developing SEPREHVIR, a tumor-targeted HSV, are pleased to announce the presentation of two posters at SITC's 30th Anniversary Annual Meeting on November 4th-8th...